We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sarah
Maguire
sarah.maguire4@nhs.net
Laura
Cutts
laura.cutts2@nhs.net
Prof
Andrew
Fisher
a.j.fisher@ncl.ac.uk
Prof
Andrew
Fisher
a.j.fisher@ncl.ac.uk
Pulmonary heart disease and diseases of pulmonary circulationChronic lower respiratory diseasesOther respiratory diseases principally affecting the interstitiumMetabolic disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Chronic respiratory diseases causes significant ill health and death within our society. It is estimated that 1 in every 7 people in the UK is affected by a respiratory disease and one of the most common chronic respiratory diseases Chronic Obstructive Pulmonary Disease (COPD) is the 5th biggest killer in the UK, responsible for over 32,000 deaths per year, a number which continues to steadily increase. This imparts a huge burden on the NHS due to both disability to individuals and the associated financial implication (£6.6 billion per year). Despite this, research into chronic lung diseases has been under-represented and underfunded for many years an issue which was highlighted in the government funded Cooksey Report in 2006. As such, our understanding of many chronic respiratory diseases including COPD, bronchiectais, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH) and cystic fibrosis (CF) remains very limited and treatments for these conditions are aimed mainly at symptom control with little impact on disease progression. It remains unlikely that any treatments which can effectively improve lung damage caused by these diseases, or even cure them, will be developed until understanding of the processes which drive them is improved. This study will recruit patients undergoing lung transplantation at the Freeman Hospital, Newcastle for end-stage chronic respiratory diseases. These patients will be asked to donate the diseased lung that is being removed which would normally be destroyed by incineration.
After this lung is removed from the patient it can be examined and samples can be taken to analyse in the laboratory.
This will enable improved understanding of the mechanisms which have caused the lung disease which in turn may highlight potential future drug treatments.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Subjects unable to give written informed consent. Subjects known or suspected to be from high risk groups either for tuberculosis, hepatitis B or HIV infection.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Laura
Cutts
laura.cutts2@nhs.net
Prof
Andrew
Fisher
a.j.fisher@ncl.ac.uk
Prof
Andrew
Fisher
a.j.fisher@ncl.ac.uk
Sarah
Maguire
sarah.maguire4@nhs.net
The study is sponsored by THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST and funded by European Commission; GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED; Medical Research Council (MRC); MedImmune, LLC; Wellcome Trust; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 12699
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
